Monoclonal antibody pharmacogenomics in cancer treatment

Abstract

Conventionally, in the pharmacokinetic/pharmacodynamic analysis of small molecule compounds such as cytotoxic anticancer drugs, polymorphism analysis of genes related to absorption, distribution, metabolism, and excretion has been performed in addition to the analyses of blood concentrations of drugs. Such pharmacogenetic factors play an important role in predicting therapeutic effects and adverse events and in the proper use of drugs. With the recent launch of immune checkpoint inhibitors (ICIs) and the rapid development of antibody-drug conjugates (ADCs) currently underway, there is no doubt that antibody drugs, which are large molecule compounds, will become key drugs in anticancer drug treatment. However, the pharmacokinetic and pharmacodynamic analysis of antibody drugs is still not sufficient, and further elucidation of factors and mechanisms affecting their dynamics in the human body is necessary. Moreover, the pharmacogenomic factors of antibody drugs have not yet been fully studied. There are many factors that should be clarified, such as factors that regulate the host immune response in ICI therapy and the effects of ATP-binding cassette transporter and cytochrome P450 on the payload of ADCs. This review provides an outline of antibody drugs in cancer treatment and summarizes the pharmacogenomic factors of antibody drugs known to date.

Keywords

Pharmacogenomics / antibody drug / antibody-dependent cellular cytotoxicity / immune checkpoint inhibitor / antibody-drug conjugate

References

[1] Frazer JK.Immunoglobulins: structure and function. Fundamental Immunology.1999;4th editionNew YorkLippincott-Raven37-74

[2] Köhler G.Continuous cultures of fused cells secreting antibody of predefined specificity..Nature1975;256:495-7

[3] Smith KG.FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications..Nat Rev Immunol2010;10:328-43 PMCID:PMC4148599

[4] Undevia SD,Ratain MJ.Pharmacokinetic variability of anticancer agents..Nat Rev Cancer2005;5:447-58

[5] Liu L.Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins..Protein Cell2018;9:15-32 PMCID:PMC5777971

[6] Brambell FW,Morris IG.A theoretical model of gamma-globulin catabolism..Nature1964;203:1352-4

[7] Brambell FW.The transmission of immunity from mother to young and the catabolism of immunoglobulins..Lancet1966;2:1087-93

[8] Simister NE.Cloning and expression of the neonatal rat intestinal Fc receptor, a major histocompatibility complex class I antigen homolog..Cold Spring Harb Symp Quant Biol.1989;54 Pt 1:571-80

[9] Akilesh S,Roopenian DC.Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism..J Immunol2007;179:4580-8

[10] Roopenian DC.FcRn: the neonatal Fc receptor comes of age..Nat Rev Immunol2007;7:715-25

[11] Sachs UJ,Braeunlich CG,Bein G.A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor alpha-chain promoter..Immunology2006;119:83-9 PMCID:PMC1782336

[12] Billiet T,Cleynen I,Ferrante M.A genetic variation in the neonatal Fc-receptor affects anti-TNF drug concentrations in inflammatory bowel disease..Am J Gastroenterol2016;111:1438-45

[13] Passot C,Renault S,Arnoult C.Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies..MAbs2013;5:614-9 PMCID:PMC3906315

[14] O'Shannessy DJ,Schweizer C,Albone E.Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer..Genomics2017;109:251-7

[15] Kaifu T.Polymorphisms of immunoglobulin receptors and the effects on clinical outcome in cancer immunotherapy and other immune diseases: a general review..Int Immunol2017;29:319-25

[16] Umana P,Moudry R,Bailey JE.Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity..Nat Biotechnol1999;17:176-80

[17] Kirin K. Poteligent technology. Available from: https://www.kyowakirin.com/biowa/out-licensing/technologies/index.html. [Last accessed on 6 Nov 2019]

[18] GlycoMAb technology. Available from: https://www.roche.ch/en/standorte/schlieren/schlieren_about_glycomab.htm. [Last accessed on 6 Nov 2019]

[19] Musolino A,Bortesi B,Capelletti M.Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer..J Clin Oncol2008;26:1789-96

[20] Tamura K,Hojo T,Kinoshita T.FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer..Ann Oncol2011;22:1302-7

[21] Hurvitz SA,Stern HM,Stinson J.Analysis of Fcgamma receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients..Clin Cancer Res2012;18:3478-86 PMCID:PMC3821872

[22] Musolino A,Dieci MV,Rimanti A.Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer..Pharmacogenomics J2016;16:472-7

[23] Cartron G,Salles G,Bardos P.Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene..Blood2002;99:754-8

[24] Weng WK.Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma..J Clin Oncol2003;21:3940-7

[25] Kim DH,Kim JG,Yang DH.FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma..Blood2006;108:2720-5

[26] Carlotti E,Oldani E,Salmoiraghi S.FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab..Haematologica2007;92:1127-30

[27] Mitroviç Z,Radman I,Sertic J.FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma..Haematologica2007;92:998-9

[28] Dornan D,Yeh RF,Dufour A.Effect of FCGR2A and FCGR3A variants on CLL outcome..Blood2010;116:4212-22

[29] Zhang W,Li J,Zhou DB.Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma..Chin Med J (Engl)2010;123:198-202

[30] Ahlgrimm M,Kreuz M,Preuss KD.The impact of Fc-gamma receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab..Blood2011;118:4657-62 PMCID:PMC3208281

[31] Fabisiewicz A,Osowiecki M,Siedlecki JA.FcgammaRIIA and FcgammaRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma..Leuk Lymphoma2011;52:1604-6

[32] Prochazka V,Gazdova J,Rozmanova S.FcγRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy..Neoplasma2011;58:263-70

[33] Ghesquieres H,Seymour JF,Offner F.Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms..Blood2012;120:2650-7

[34] Persky DO,Goldman BH,Fisher RI.Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone..Haematologica2012;97:937-42 PMCID:PMC3366663

[35] Varoczy L,Gyetvai A,Gergely L.Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol..Pathol Oncol Res2012;18:43-8

[36] Ghesquieres H,Haioun C,Verney A.FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts..Hematol Oncol2017;35:447-55 PMCID:PMC5716925

[37] Liu F,Jin X,Deng L,Zhu J.FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma..DNA Cell Biol2014;33:616-23 PMCID:PMC4144364

[38] Gong J,Reddi S.Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations..J Immunother Cancer2018;6:8 PMCID:PMC5778665

[39] Havel JJ,Chan TA.The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy..Nat Rev Cancer2019;19:133-50 PMCID:PMC6705396

[40] Alexandrov LB,Wedge DC,Behjati S.Signatures of mutational processes in human cancer..Nature2013;500:415-21 PMCID:PMC3776390

[41] Snyder A,Merghoub T,Zaretsky JM.Genetic basis for clinical response to CTLA-4 blockade in melanoma..N Engl J Med2014;371:2189-99 PMCID:PMC4315319

[42] Rizvi NA,Snyder A,Makarov V.Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer..Science2015;348:124-8 PMCID:PMC4993154

[43] Van Allen EM,Schilling B,Blank C.Genomic correlates of response to CTLA-4 blockade in metastatic melanoma..Science2015;350:207-11 PMCID:PMC5054517

[44] Yarchoan M,Jaffee EM.Tumor mutational Burden and response rate to PD-1 inhibition..N Engl J Med2017;377:2500-1 PMCID:PMC6549688

[45] Le DT,Wang H,Kemberling H.PD-1 blockade in tumors with mismatch-repair deficiency..N Engl J Med2015;372:2509-20 PMCID:PMC4481136

[46] Le DT,Smith KN,Bartlett BR.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade..Science2017;357:409-13 PMCID:PMC5576142

[47] Chowell D,Grigg CM,Samstein RM.Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy..Science2018;359:582-7 PMCID:PMC6057471

[48] Rodig SJ,Jackson DG,Giobbie-Hurder A.MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma..Sci Transl Med2018;10:eaar3342

[49] Elias DJ,Kline LE,Dillman RO.Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma..Cancer Res1990;50:4154-9

[50] Trail PA,Lasch SJ,Hofstead S.Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates..Science1993;261:212-5

[51] Sievers EL.Mylotarg: antibody-targeted chemotherapy comes of age..Curr Opin Oncol2001;13:522-7

[52] Ravandi F.Gemtuzumab ozogamicin: one size does not fit all--the case for personalized therapy..J Clin Oncol2011;29:349-51

[53] Panowski S,Raab H,Junutula JR.Site-specific antibody drug conjugates for cancer therapy..MAbs2014;6:34-45 PMCID:PMC3929453

[54] Dosio F,Cattel L.Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components..Toxins (Basel)2011;3:848-83 PMCID:PMC3202854

[55] Sehn LH,Matasar MJ,McMillan A.Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) improves outcomes in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) versus BR alone: results from a randomized phase 2 study..Blood2017;130:2821

[56] Deeks ED.Polatuzumab vedotin: first global approval..Drugs2019;79:1467-75 PMCID:PMC6794237

[57] Tamura K,Takahashi S,Krop IE.Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study..Lancet Oncol2019;20:816-26

[58] Cianfriglia M.The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin..Ann Ist Super Sanita2013;49:150-68

[59] Loganzo F,Sung M,Myers JS.Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments..Mol Cancer Ther2015;14:952-63

[60] Shimizu T,Yonemori K,Shimomura A.First-in-human (FIH) phase 1 (Ph1) study of MORAb-202 in patients (pts) with advanced folate receptor alpha (FRA)-positive solid tumors..J Clin Oncol2019;37:5544

[61] Kim S,Park S,Paek K.Drifts in ADCC-related quality attributes of Herceptin(R): impact on development of a trastuzumab biosimilar..MAbs2017;9:704-14 PMCID:PMC5419076